Feelings of Anti-stampede Safety Education
Release time:
2022-12-04
This year # February 9 is the 31 National Fire Day, with the theme of "Grasp Fire Safety and Guarantee High Quality Development " . As in previous years, our company organized and watched the fire safety warning education film. Fire, electric shock, mechanical injury, high falling injury, limited space toxic gas chemical injury ... Every accident is shocking, shocking the soul, every blood lessons should be learned, everyone should establish the idea of safety from the drip grab. In addition to these contents, this year has also specially increased the knowledge training on preventing stampede accidents. On the evening of
10, a major stampede occurred in the well-known business district of Seoul, South Korea, causing at least 156 deaths and 152 injuries, including 4 Chinese citizens. I believe everyone has learned about this from the media. In the sigh, have we ever thought about what we should do to protect ourselves effectively if we are in such an environment? The torture and remembrance of security should not stop, we don't want a disaster to happen, but when it comes, we need to know how to deal with it.
First of all, we should pay attention to what are the crowded places. Theater, KTV , stadiums, large shopping malls, etc., do know fairly well. When we enter these people-intensive places, we have to imagine a preliminary plan in our minds. In case of emergency, where should I run and where are the safety exits? Keep these exits and locations in mind.
Secondly, we should try our best to avoid going to the crowded crowd and walk on the edge of the crowd when we have. Be civilized, not crowded, not heckling, not creating tension or terror when there are many people. In a crowded crowd, always be vigilant. When you find that the crowd starts to stir, you must be prepared to protect yourself.
should avoid danger when trampled on, and insist on "3 " "4 " . To escape, see the crowded situation, can not go up to join the fun, to quickly leave the scene, and when fleeing, do not blindly follow the surrounding people moving. To hide, when you find it crowded, you should immediately avoid it and choose a safe place to stay for a short time. To stabilize, if you are already caught in a crowd, you must first stabilize your feet and try to lean against a wall or grab a solid object such as a telephone pole to stabilize your body.
Don't shout. Don't shout at random when crowded. This will aggravate the panic of the crowd. No retrograde, in the event of an accident, do not run against the flow of people. Don't squat, when crowded, try not to use the posture of leaning forward or low center of gravity, even if money and things fall off, don't bend down to pick it up rashly. Do not suffocate. When moving forward in a crowded crowd, use one hand to hold the other wrist, stretch your elbows flat on your chest, and bend forward slightly to form a certain space to keep breathing smooth.
Finally, let's remember the 24-character tactic of self-help in stampede: lie on your side urgently, buckle your neck with your hands, protect your head, curl up into a ball, fold your legs, and tighten your whole body.
After learning this knowledge, I feel that I have gained a lot. I hope we will never use it, but we can't.
(Luo Meiyan)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31